Casi Pharmaceuticals, INC. (CASIF) — 6-K Filings

All 6-K filings from Casi Pharmaceuticals, INC.. Browse 39 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (39)

6-K Filing — Apr 20, 2026
CASI Pharmaceuticals Files 6-K Report — Apr 15, 2026 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 15, 2026, reporting information as a foreign issuer. The filing includes standard documents and details the
6-K Filing — Dec 31, 2025
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — Dec 23, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on December 23, 2025, reporting for the month of December 2025. The filing incorporates by reference information fro
6-K Filing — Dec 11, 2025
6-K Filing — Nov 19, 2025
6-K Filing — Nov 14, 2025
CASI Pharmaceuticals Files 6-K Report — Nov 10, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on November 10, 2025, reporting information for the month of November 2025. The filing is a Report of Foreign Privat
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — Sep 26, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 26, 2025, reporting for the month of September 2025. This filing incorporates by reference information
CASI Pharmaceuticals Files 6-K Report — Sep 2, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 2, 2025, for the month of September 2025. This filing is a report of a foreign private issuer and incor
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — Aug 29, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 29, 2025, to incorporate by reference information from Exhibits 99.1 into its existing Registration Statem
CASI Pharmaceuticals Files 6-K, Incorporates into F-3 Filings — Aug 27, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 27, 2025, to report information for the month of August 2025. The filing is incorporated by reference into
CASI Pharmaceuticals Files August 2025 Report — Aug 4, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 4, 2025, reporting information for the month of August 2025. The filing includes a press release dated Aug
CASI Pharmaceuticals Files 6-K, Incorporates by Reference — Jul 22, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 22, 2025, for the month of July 2025. This report is incorporated by reference into the Company's Registrati
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — May 20, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 20, 2025, incorporating by reference information from Exhibits 99.1 and 99.2 into its Registration Statements
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — May 16, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 16, 2025, incorporating by reference information from Exhibit 99.1 into its existing F-3 Registration Stateme
CASI Pharmaceuticals Announces Management Change — May 14, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced a change in its management team on May 14, 2025. The company, focused on biopharmaceutical development and commercializatio
CASI Pharmaceuticals Files May 2025 6-K Report — May 12, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 12, 2025, reporting for the month of May 2025. The filing includes a press release dated May 12, 2025, as Exh
CASI Pharmaceuticals Files 6-K Report — May 7, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 7, 2025, to report a press release dated May 7, 2025. The filing itself does not contain specific financial f
CASI Pharma ends NY litigation, demands arbitration vs Acrotech — Apr 9, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced on April 9, 2025, the discontinuance of its New York litigation proceeding against Acrotech and initiated a demand for arbi
CASI Pharmaceuticals Files April 2025 6-K Report — Apr 3, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 3, 2025, reporting information for the month of April 2025. The filing includes a press release dated April
CASI Pharmaceuticals Files March 2025 Report — Mar 31, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on March 31, 2025, reporting on activities for the month of March 2025. The filing includes a press release dated Ma
CASI Pharma Gets Interim Relief in Juventas Dispute — Feb 10, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced on February 10, 2025, that it has received interim relief in a dispute with Juventas. The company is a biopharmaceutical fi
CASI Pharmaceuticals Faces Asset Freeze in China — Jan 21, 2025 Risk: high
On January 21, 2025, CASI Pharmaceuticals, Inc. announced it received an asset freezing order from a court in the People's Republic of China. The filing does no
CASI Pharma's CID-103 Faces FDA Clinical Hold — Dec 26, 2024 Risk: high
On December 26, 2024, CASI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its investigational dr
CASI Pharma Receives Evomela License Termination Notice — Dec 16, 2024 Risk: medium
On December 13, 2024, CASI Pharmaceuticals, Inc. received a termination process letter from Acrotech regarding the license of Evomela®. This action follows Acro
CASI Pharmaceuticals Files 6-K with Press Release — Nov 15, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on November 15, 2024, to report information as a foreign private issuer. The filing includes a press release dated N
CASI Pharmaceuticals Announces Senior Management Changes — Sep 12, 2024 Risk: low
On September 12, 2024, CASI Pharmaceuticals, Inc. announced changes in its senior management. The company, incorporated in the Cayman Islands, is based in Beiji
CASI Pharmaceuticals Files August 2024 6-K Report — Aug 16, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 16, 2024, reporting for the month of August 2024. The filing is from their principal executive office in B
CASI Pharma Secures Asset Freeze Against Juventas — Jul 19, 2024 Risk: medium
On July 19, 2024, CASI Pharmaceuticals, Inc. announced it obtained an asset freezing order from a court in the People's Republic of China against Juventas. This
CASI Pharmaceuticals Files 6-K for July 2024 — Jul 8, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 8, 2024, reporting information for the month of July 2024. The company, previously known as CASI Pharmaceuti
CASI Pharmaceuticals Files 6-K — Jun 27, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on June 27, 2024, reporting information as a foreign private issuer. The filing indicates the company operates in th
CASI Pharmaceuticals Files 6-K Report — May 15, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 15, 2024, reporting on activities for the month of May 2024. The company, previously known as CASI Pharmaceut
CASI Pharmaceuticals Files 6-K Report — Apr 8, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 8, 2024, reporting its status as a foreign private issuer. The company, previously known as CASI Pharmaceut
CASI Pharmaceuticals Files 6-K, Notes Name Change — Mar 28, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on March 28, 2024, to report its status as a foreign private issuer filing annual reports under Form 20-F. The filin
CASI Pharmaceuticals Faces Nasdaq Delisting — Mar 13, 2024 Risk: high
CASI Pharmaceuticals, Inc. received a notice on March 13, 2024, indicating that its common stock would be delisted from the Nasdaq Capital Market due to its fai
CASI Pharmaceuticals Files February 2024 6-K Report — Feb 29, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on February 29, 2024, reporting on its activities for the month of February 2024. The filing indicates the company i
CASI Pharma CCO Fuqiang Zhang Resigns; No Immediate Replacement Planned — Feb 12, 2024 Risk: medium
CASI Pharmaceuticals, Inc. announced on February 8, 2024, that Mr. Fuqiang Zhang resigned as Chief Commercial Officer (COO) with immediate effect. The company s
CASI Pharma Appoints Huang Hai as Global CCO & China GM — Jan 30, 2024
CASI Pharmaceuticals, Inc. announced on January 29, 2024, the appointment of Mr. Huang Hai as Global Chief Commercial Officer and General Manager of CASI China,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX